|
|
|
Cancer- The Real Facts
Cancer has a fearsome reputation. Not without reason either. It is a disease that has not yet fully yielded to the skills and intelligence of medical scientists and doctors. And, as if the pain from the disease is not enough, the treatment for...
CLA - Weight Loss Wonder
~CLA - Weight Loss Wonder Trade name "Tonalin" - CLA (Conjugated Linoleic Acid) is a naturally occurring fatty acid that is found in primarily meat and dairy products, and is also derived from safflower oil. CLA has gained a lot of attention in the...
Dog Genome May Shed Light On Human Disease
Scientists have succeeded in sequencing the dog genome, an accomplishment that could lead to better health for humans as well as canines. An international team of researchers have published their detailed analysis in the journal Nature.
"Of the...
Hormone Replacement Therapy And Breast Cancer
You have permission to publish this article electronically or in print, free of charge, as long as the byline is included. A courtesy copy of your publication would be appreciated. HORMONE REPLACEMENT THERAPY AND BREAST CANCER: THE RISKS IN...
Your Worst Enemy
When it comes to the state of your health, you may be your own
worst enemy.
This is actually good news. You may not be able to control how
others treat you, but you certainly have control over the way
you treat yourself! In order to treat...
|
|
| |
|
|
|
|
New Treatments that Offer Increased Hope for Osteoporosis Patients
(ARA) - For a time, hormone replacement therapy (the administration of estrogen either alone or in combination with other hormones) served as the preferred treatment for post-menopausal women hoping to reduce the progression of osteoporosis, a debilitating and inevitable bone-thinning disorder. Yet the latest findings from the prematurely halted Women’s Health Initiative (WHI) study on hormone replacement therapy alarmed many women. The study concluded that an estrogen and progestin combination used by thousands increased the risk of breast cancer, blood clots, heart attacks, and strokes when taken over a long period of time.
Osteoporosis is drastically accelerated during menopause and is the third leading cause of death of women over 70. By age 55, the average woman has already lost 30 percent of her bone mass. Eventually, bone loss can progress to the point where bones become so thin that they are susceptible to fracture from even the slightest trauma. According to the National Osteoporosis Foundation, one out of every two women over the age of 50 will have an osteoporosis-related fracture in her lifetime. Caucasian and Asian women are more likely to develop osteoporosis. However, African American and Hispanic women are at significant risk for developing the disease. Additionally, small-boned and thin women (under 127 pounds) are at greater risk for osteoporosis.
Many women are now searching for a safe alternative to hormone replacement therapy to alleviate the effects of osteoporosis. Current treatments on the market such as bisphosphonates and SERMs (estrogen-related therapies) have safety issues and focus primarily on slowing bone loss. Another existing treatment option is calcitonin, a naturally occurring hormone involved in calcium regulation and bone metabolism. In women who are more than five years beyond menopause calcitonin slows bone loss, increases spinal bone density and, according to recent studies, reduces the risk of spinal
fractures. In recent trials, calcitonin demonstrated a 62 percent reduction in the incidence of new vertebral fractures for a subgroup of women over 75, one of the most significant reductions demonstrated by any current osteoporosis therapy. In addition, calcitonin is the only osteoporosis therapy that can reduce the significant bone pain often associated with osteoporosis. Because calcitonin is a peptide, it cannot be taken orally because it would be digested before it could exert its therapeutic effect. Currently calcitonin is available as an injection or nasal spray. The U.S. Food and Drug Administration (FDA) is currently reviewing FORTICAL, a unique nasal calcitonin product developed by Unigene Laboratories, and Unigene is also developing an oral form of the product.
A new therapeutic option is parathyroid hormone (PTH), which can rebuild bone mass that has been lost due to osteoporosis. PTH has proven to increase the volume and strength of honeycomb-shaped bone mass located within the bone. This inner mesh contains blood vessels and bone marrow and begins to diminish after menopause. PTH helps reduce the incidence of fractures by restoring some of the lost bone architecture. Currently, PTH therapy is available only via daily injections. Unigene Laboratories and GlaxoSmithKline are jointly developing a PTH treatment that can be administered orally.
“Calcitonin has a proven, 25-year record of safe human use with virtually no side effects, and can be taken simultaneously with other medications,” said Dr. Warren Levy, president and CEO of Unigene. “After the WHI study, safety has become an even more important consideration because once a therapy is initiated, it should ideally be taken for life.”
For more information on osteoporosis and treatment options, please log on to www.unigene.com.
Courtesy of ARA Content
About the author:
Courtesy of ARA Content
|
|
|
|
|
|